Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy

Clinical trial NCT06711068 · RECRUITING

Trial details

NCT number: NCT06711068
Sponsor: Shu Wang
Status: RECRUITING
Study type: OBSERVATIONAL

HER2-positive Breast Cancer

Start date: 2019-01-01
Primary completion: 2031-12-31
Enrollment: 8077

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.